Member Info for Energyshares

The Avacta board have their plan and licence agreements will be ready to sign as soon as p1b starts to show efficacy results.

But the SP at the moment could scupper their plans with an opportunist hostile bid coming from a big Pharma firm who are not at the table.

GLA

This report dated 10/05/2023

Gives an insight into the amount of companies and pipelines involved in STS.

NEWS PROVIDED BY

DelveInsight Business Research, LLP

10 May, 2023, 11:00 ET

Key soft tissue sarcoma companies and key soft tissue sarcoma pipeline therapies.

Avacta is not listed but it does get a paragraph about being granted ODD by the FDA.

Once P1a PK data is released and P1b starts a lot of eyes will be on Avacta.

In September 2022, Avacta Group plc announced that the US Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) to the company's lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma.AVA6000 is a form of the generic chemotherapy doxorubicin that has been modified using the pre|CISION technology so that it is activated predominantly in the tumor with the aim of sparing healthy tissue from exposure and improving the safety, tolerability, and efficacy of the drug.

https://www.prnewswire.com/news-releases/soft-tissue-sarcoma-pipeline-space-brims-with-novel-emerging-therapies-with-over-125-key-companies-working-in-the-domain--delveinsight-301820474.html

GLA not long now…

Feb 2020

Avacta has come a long way since this clip.

£1.03

Market is still thick as mince.

https://avacta.com/alastair-smith-provides-overview-of-precision-prodrug-technology-and-update-on-ava6000-clinical-trial/

Avacta’s first licencee for Pre/Cision pipeline are very excited about the future

“no-brainer for those who recognize the immense growth potential in the biopharmaceutical sector”

The company's innovative product pipeline and exclusive CanSEEK technology offer groundbreaking cancer treatments that address unmet clinical needs, positioning POINT for leadership in the biopharma industry.

The unique and innovative approach to harness CanSEEK technology in their treatments, aimed at improving specificity and reducing off-target effects, highlights their cutting-edge approach and potential for market leadership in the future.

We believe investing in POINT Biopharma should be a no-brainer for those who recognize the immense growth potential in the biopharmaceutical sector, particularly in the development of radioligand therapies. This investment opportunity is further bolstered by the company's impressive financials, as demonstrated by their considerable research and development (R&D) investments, exceptional cash holdings, and responsible financial management. With such a unique approach to targeting cancer and a financial standing to propel their vision forward, POINT Biopharma Global Inc. represents an investment thesis worth considering for any discerning investor in the oncology space in our view.

https://seekingalpha.com/article/4606046-point-biopharma-navigating-the-landscape-with-strong-financials

Every new Big Pharma licencee will be locking in and securing their market share with each new Pre/Cision drug.

So how much is the platform worth ?

GLA just sit on your Alister Wonka golden tickets…

Wearegroot

Good luck with £14, I think this could be achieved.

My guess for a bit of fun you have either

A) 71,428 shares

B) 35,714 shares

C) 17,857 shares

Your target £1 million

£500,000 or £250,000

When someone makes a random price prediction it’s always based on their exit price.

Again good luck

I found this medical journal from June 2023, but when you copy link it takes you to a paywall.

To avoid paywall

Go to google and search

Jnm ava6000

It’s Journal of Nuclear Medicine.

Paper is 281 pages long but page 15 Avacta gets a mention lots of research going around on FAP at the moment.

Looks very promising for Avacta to be one of the leaders in this field.

apologies if this has been mentioned before.

https://jnm.snmjournals.org/content/jnumed/64/7/local/complete-issue.pdf

If we are quiet we’re getting on with it.

Ignore the FUD

Courtesy of RMFatGB

Alistair stated during the on-line video presentation that: 

“We are seeing therapeutically significant levels of Dox in the tumour biopsies”. To repeat, as Alistair did, “THERAPUTICALLY SIGNIFICNT LEVELS”. 

Alistair goes on to say, “we know the levels of doxorubicin required to make the drug work and the levels we are seeing in the biopsies are greater. That’s what we can say factually now”. Alistair goes on to say, “Why the H*ll wouldn’t it work”? 

Watch the AGM video from 1:04:25 – 1:08:50 https://www.youtube.com/watch?v=DlHRRmycxTY

Energy, rather than make a silly jibe,

WTF is that

“ The problem I have is that AS moves about a bit when he talks.”

‘The problem I have is that AS moves about a bit when he talks.”

And you don’t clap and honk when you see a fish….

🦭🦭🦭🦭🦭🦭🦭🦭🦭

Sarcoma UK logo looks familiar

https://twitter.com/sarcoma_uk?s=11

Author is Charles Archer….

He was skating Avacta a few weeks ago this is just his blog

Super positive then negative then positive

Like most traders ……

Author Charles Archer….

Super positive then negative then positive

Like most traders ……

Courtesy of RMFatGB

Alistair stated during the on-line video presentation that: 

“We are seeing therapeutically significant levels of Dox in the tumour biopsies”. To repeat, as Alistair did, “THERAPUTICALLY SIGNIFICNT LEVELS”. 

Alistair goes on to say, “we know the levels of doxorubicin required to make the drug work and the levels we are seeing in the biopsies are greater. That’s what we can say factually now”. Alistair goes on to say, “Why the H*ll wouldn’t it work”? 

Watch the AGM video from 1:04:25 – 1:08:50 https://www.youtube.com/watch?v=DlHRRmycxTY

Seen a lot on here and twitter lately asking why Avacta hasn’t licenced out Pre/Cision yet.

LTH’s who are fully researched know the reason….

For the lazy researched:

Yes they have licenced Pre/Cision first deal was with Point Bio who are about to send their CanSeek into the clinic.

Avacta had a game plan to licence everything and collect royalties .

We were all expecting AVA6000 to be licenced out last year.

But last June, Avacta started to see results coming in from phase 1a and they are seeing data that has surpassed everything they excepted.

Avacta changed their strategy and they now want to take AVA6000 as far as they can to maximise SH value.

So to any newbies or the poorly researched stop worrying about licence deals they will come very soon if a T/O doesn’t come first.

Just hold for Gold and ignore the noise.

GLA…..

Once MTD is known, I don’t think it will take long to find patients for phase 1b.

The majority of Cohort 5 were STS patients.

Phase 1b

Estimated Enrollment :

80 participants:

At MSK, we see more than 600 new patients with soft tissue sarcoma each year.

People with advanced soft tissue sarcoma may benefit from leading-edge therapies, such as immunotherapy or targeted therapy. These are often offered through clinical trials. MSK runs one of the largest soft tissue sarcoma clinical trial programs in the United States.

https://www.mskcc.org/cancer-care/types/soft-tissue-sarcoma

GLA

BITL

Good shout EF.

AS answered the questions really well confident and honest.

He could of had 100 questions today and replied 99 with a great answer.

But Avacta have this sick following, headed by the teeth guy and they will manipulate that one wrong answer.

AS has enough experience to realise questions about SP and market size should just be diplomatically answered.

Trolls if your reading Avacta are about to blow the doors off tumours get out of your shorts before it’s too late.

GLA

AS is a great scientist and is doing an astounding job with the rest of the board.

But he needs to Hand over these presentations to a pro who can deal with the markets.

Yet again he has fell foul to AIM small investors moaning again this time at the AGM about SP market size and “ Are we there yet” attitude.

AS was just trying to explain about biotechs and valuations and where Avacta are sitting at this present time.

But he should of realised there is a lot of traders and trolls and MM’s who will hang on to his every word and will manipulate the SP for any negative comments from the company.

Just load up and wait great investment for pension or ISA’s

GLA

Https://cancercenters.cancer.gov/Documents/MSKCCDSMP508C.pdf

Avacta also have another safety committee to deal with MSKC have their own DSMC consisting of 22 members and also a DSMB to scrutinise the trial.

Page 15

Also on Page 18

4 to 6 precipitants are audited on each trial.

That’s a lot of committee members to keep any emerging positive data under wraps.

GLA

“Several patients remain on trial in different dose cohorts and continue to receive AVA6000 as their disease has not progressed”

GLA

If news starts to leak that AVA6000 patients are progression free on the trial.

All the patients that tried to enrol and were turned down from joining the trial could try this route.

FDA’s Expanded Access Program allows patients with life-threatening diseases or conditions such as cancer try investigational medical products (drug, biologic, or medical device) when no satisfactory therapies are available and there is no opportunity for the patient to enroll in a clinical trial.

https://www.fda.gov/about-fda/oncology-center-excellence/project-facilitate